The Fellow on Call: The Heme/Onc Podcast
Episode 126: AML Series, Pt 12 - Treatment of patients with relapsed/refractory disease
Jan 8, 2025
The hosts dive into the complex world of relapsed and refractory acute myeloid leukemia, discussing how to define primary induction failure and exploring various treatment options. They highlight innovative strategies like FLAG and CLAG regimens to enhance cytarabine's effectiveness. The conversation also addresses the role of targeted therapies and the significance of clinical trials in improving outcomes. Personal stories add a relatable touch, making this evolving treatment landscape even more engaging.
00:00
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The treatment landscape for relapsed and refractory AML is rapidly evolving, with new therapies like venetoclax combining with hypomethylating agents showing promise.
- Understanding primary induction failure in AML is critical, as different definitions impact treatment strategies and patient prognosis significantly.
Deep dives
Understanding Relapse and Refractory AML
Relapsed and refractory acute myeloid leukemia (AML) presents significant challenges in treatment and patient management. Primary induction failure occurs when there is persistent disease despite intensive chemotherapy. In this context, definitions of treatment failure differ based on treatment intensity, with the European Leukemia Network (ELN) providing guidance for managing these cases. Importantly, prognosis is particularly poor for patients with specific mutations like TP53, highlighting the necessity of refining treatment strategies.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
